| Literature DB >> 33783211 |
Andrew C Flick1, Carolyn A Leverett2, Hong X Ding3, Emma McInturff2, Sarah J Fink4, Subham Mahapatra2, Daniel W Carney1, Erick A Lindsey1, Jacob C DeForest5, Scott P France2, Simon Berritt2, Simone V Bigi-Botterill1, Tony S Gibson1, Yiyang Liu2, Christopher J O'Donnell2.
Abstract
New drugs introduced to the market are privileged structures having affinities for biological targets implicated in human diseases and conditions. These new chemical entities (NCEs), particularly small molecules and antibody-drug conjugates, provide insight into molecular recognition and simultaneously function as leads for the design of future medicines. This review is part of a continuing series presenting the most likely process-scale synthetic approaches to 40 NCEs approved for the first time anywhere in the world in 2019.Entities:
Year: 2021 PMID： 33783211 DOI： 10.1021/acs.jmedchem.1c00208
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446